title: Ticagrelor for the treatment of atherosclerotic disease: insights from the PARTHENON clinical development program.
abstract: Ticagrelor (P2Y12 receptor antagonist) is presently indicated for preventing atherothrombotic events in patients with acute coronary syndrome and patients with a history of myocardial infarction. The PARTHENON clinical development program comprises five randomized, controlled, cardiovascular, indication-seeking outcome studies, aiming to evaluate ticagrelor across the spectrum of patients with atherothrombotic disease. Results of two large-scale trials support a benefit for ticagrelor in patients with acute coronary syndrome (PLATO; ClinicalTrials.gov: NCT00391872) and in patients with a history of myocardial infarction (PEGASUS-TIMI 54; ClinicalTrials.gov: NCT01225562). Ongoing trials will provide information on the efficacy and safety of ticagrelor in patients with acute ischemic stroke or transient ischemic attack (SOCRATES; ClinicalTrials.gov: NCT01994720), peripheral artery disease (EUCLID; ClinicalTrials.gov: NCT01732822) and coronary artery disease in patients with Type 2 diabetes mellitus (THEMIS: ClinicalTrials.gov: NCT01991795).
authors.affiliation: Global Medicines Development, AstraZeneca Gothenburg, Pepparedsleden 1, SE-431 83 Mölndal, Sweden.
authors.forename: Peter
authors.initials: P
authors.lastname: Held
authors.affiliation: Global Medicines Development, AstraZeneca Gothenburg, Pepparedsleden 1, SE-431 83 Mölndal, Sweden.
authors.forename: Anders
authors.initials: A
authors.lastname: Himmelmann
authors.affiliation: Global Medicines Development, AstraZeneca Gothenburg, Pepparedsleden 1, SE-431 83 Mölndal, Sweden.
authors.forename: Marc
authors.initials: M
authors.lastname: Ditmarsch
mesh_terms: D054058:Acute Coronary Syndrome / Q000150:complications*; D000241:Adenosine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D050197:Atherosclerosis / Q000188:drug therapy*; D003924:Diabetes Mellitus, Type 2 / Q000150:complications; D006801:Humans; D009203:Myocardial Infarction / Q000150:complications; D058921:Purinergic P2Y Receptor Antagonists / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D000077486:Ticagrelor; D016896:Treatment Outcome
chemical_list: D058921:Purinergic P2Y Receptor Antagonists; D000077486:Ticagrelor; D000241:Adenosine
keywords: P2Y12 receptor antagonist; acute coronary syndrome; atherosclerosis; coronary artery disease; diabetes mellitus; ischemic stroke; myocardial infarction; ticagrelor